Home Blog Page 2085

Save Now, Travel through March: T’way Air Announces Fall Savings to Korea

By
Advertorial Desk
-

Promo Code FLYOCT & Special Coupons for Travel through March 2026

TAIPEI, Oct. 20, 2025 /PRNewswire/ — T’way Air, Korea’s leading low-cost carrier, invites travelers to enjoy special savings through October 31 on Taiwan-Korea bookings for travel until March 28, 2026.

Save Now, Travel through March: T’way Air Announces Fall Savings to Korea
Save Now, Travel through March: T’way Air Announces Fall Savings to Korea

T’way Air currently operates seven direct flights to Korea: Songshan–Gimpo (Seoul), Taipei–Jeju, Taipei–Daegu, Taichung–Incheon (Seoul), Kaohsiung–Gimpo (Seoul), Kaohsiung–Incheon (Seoul), and Kaohsiung–Jeju. Full route maps and flight schedules are available at twayair.com.

T’way Air is offering the following offers until October 31:

  • Up to 15% Off Promo Code: enter promo code FLYOCT when booking, for travel through March 28, 2026. (actual savings may vary with the exchange rate at purchase).
  • First-Come TWD 500 Off Coupon: bookings of TWD 5,000 or more, travel through March 28, 2026; valid on Taipei–Jeju, and Kaohsiung–Jeju
  • TWD 300 Off Coupon: bookings of TWD 3,000 or more, travel through March 28, 2026.
  • TWD 800 Off Coupon: bookings of TWD 7,000 or more, travel through March 28, 2026.
  • TWD 400 Early Bird Coupon: bookings of TWD 3,000 or more, travel period December 1 – March 28, 2026.
  • TWD 900 Early Bird Coupon: bookings of TWD 7,000 or more, travel period December 1 – March 28, 2026.

Start in Myeongdong for street food and nonstop shopping. Walk the fortress wall in Naksan Park for sunset views, and look over the Seoul skyline from N Seoul Tower. Then try local favorites – gimbap, naengmyeon, seollongtang, and Korean hot dog – all close to major shopping and cultural hotspots. With T’way Air flights to Korea, planning a culture-rich trip is easy, and the Korean Wave adds to the fun. For a change of pace, head to Jeju Island for coastal trails and a relaxed vibe beloved by locals.

For full flight schedules, coupon terms, and booking details, visit twayair.com. T’way Air currently serves 60 destinations worldwide and continues to expand its network.

About T’way Air

T’way Air Co., Ltd., headquartered in Daegu, South Korea, is a leading low-cost carrier (LCC) providing affordable and reliable air travel since 2010. T’way Air serves customers across East Asia, Southeast Asia, Central Asia, Oceania, and Europe with a modern fleet of Boeing 737-800s, 737 MAX 8s, and Airbus A330-300, A330-200, and Boeing 777-300ERs. T’way Air continues to expand its global network, offering great value to passengers worldwide. For more information, please visit www.twayair.com.

Media Contact

T’WAY AIR Public Relations

twaypr@twayair.com

China’s enduring commitment to peaceful development: a consistent path across past, present, and future

By
Advertorial Desk
-

BEIJING, Oct. 20, 2025 /PRNewswire/ — A report from People’s Daily:

Amid a turbulent and rapidly evolving global landscape, one principle remains consistent in China’s international engagement: its unwavering commitment to peaceful development. This steadfast approach continues to position China as a stabilizing force for global peace and progress.

China recently hosted the largest-ever Shanghai Cooperation Organization (SCO) summit in history and put forward the Global Governance Initiative, reinforcing its support for more inclusive and effective international systems.

The country solemnly commemorated the 80th anniversary of the victory in the Chinese People’s War of Resistance Against Japanese Aggression and the World Anti-Fascist War, joining the international community in remembering history and safeguarding peace.

Simultaneously, China has advanced cooperation through platforms such as BRICS and the United Nations, announced new nationally determined contributions at the UN Climate Change Summit, and launched fresh initiatives to support global women ‘s development at the Global Leaders’ Meeting on Women.

China not only firmly follows the path of peaceful development but also actively contributes to global stability and positive momentum for peace and development.

The pursuit of peace and development is deeply rooted in Chinese civilization, which has long valued harmony and aspired for universal peace. Despite enduring a century of national humiliation, China emerged with a strengthened resolve to safeguard peace, not to pursue aggression or dominance.

History affirms that peaceful development is not only a national choice but a universal truth. The enduring aspirations of humanity for peace, development, fairness, justice, democracy, and freedom continue to guide collective progress. Even in times of disruption, history shows that solidarity enables the international community to restore and advance its course.

In today’s uncertain international environment, the call for peace and development remains both morally imperative and globally supported. The historical trend toward building a community of shared future for humanity remains firmly on track.

Looking ahead, China remains firmly committed to its path of peaceful development, while actively contributing to global peace and development.

China’s role in promoting peace and development is evident in its commitment to shared growth. Recently, China announced at the UN headquarters in New York that it will not seek any new special and differential treatment in current and future WTO negotiations. This solemn decision demonstrates its commitment to upholding the multilateral trading system and its sincere desire to promote common development.

China also addresses global security challenges through tangible actions. From active participation in UN peacekeeping missions to successfully facilitating the Saudi Arabia–Iran rapprochement, and consistently advocating political resolutions to the Ukraine and Palestinian-Israeli conflicts, China demonstrates its firm commitment to international peace.

Equally important is China’s embrace of dialogue and mutual learning among civilizations. This year, the first International Day for Dialogue among Civilizations was marked by themed events held simultaneously in New York, Geneva, Vienna, Nairobi, Paris, Bangkok, and The Hague. China has also hosted the Global Civilizations Dialogue Ministerial Meeting, the fourth Dialogue on Exchanges and Mutual Learning among Civilizations, and the Beijing Culture Forum. Together, these platforms have fostered understanding, cooperation, and peaceful exchange among nations.

Moreover, China contributes to global governance reform by advocating for a system based on sovereign equality rather than hegemonic dominance. The Global Governance Initiative proposed by China aims to build a more just and equitable global governance system and provide a solid foundation for sustained global peace and development.

Chinese modernization follows the path of peaceful development. China will continue to serve as a force for global peace, stability and progress. Looking ahead, if all nations uphold peaceful development, cooperate to safeguard global stability, and work together toward building a community with a shared future for humanity, the collective journey of humanity will advance toward a brighter and more promising future.

CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer at ESMO Congress 2025

By
Advertorial Desk
-

SHANGHAI, Oct. 20, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research results of the Phase Ib registrational clinical trial of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell product candidate against protein Claudin18.2) for pancreatic cancer (PC) adjuvant therapy in China (CT041-ST-05, NCT05911217) has been presented in poster session at European Society for Medical Oncology (ESMO) Congress 2025. The poster was titled “Adjuvant Therapy with Claudin18.2-specific CAR T Cells (Satri-cel) in High-Risk Pancreatic Cancer (CT041-ST-05)” (Poster number: 2220P). The trial represents the world’s first proof-of-concept (POC) study exploring CAR T-cell therapy for the adjuvant treatment of solid tumors. Professor Xianjun Yu from Fudan University Shanghai Cancer Center serves as the principal investigator.

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dismal prognosis even among patients who undergo surgical resection. Local recurrence and distant metastasis are common, often leading to treatment failure. Elevated carbohydrate antigen 19-9 (CA19-9) levels post resection indicate aggressive tumor biology and higher risk of recurrence. The median interval is approximately 3 months between CA19-9 elevation and radiological recurrence. [1][2] Current standard adjuvant therapies have limited effectiveness for high-risk patients, highlighting the urgent need for novel strategies.

This trial enrolled patients with Claudin18.2 positive PDAC who have undergone curative-intent resection, with abnormal CA19-9 after 3 months adjuvant chemotherapy and no evidence of recurrence. From Sep 15, 2023 to April 11, 2025 (data cut-off date), six patients received satri-cel infusion and completed at least 4 weeks of follow-up.

With a median follow-up of 6.05 months from infusion, only one patient experienced disease recurrence, while others are still under disease free. The median disease-free survival (DFS) and median overall survival (OS) were not reached (NR). The 9-month DFS rate from surgery was 83.3%. Notably, one patient who has completed 52-week follow-up post infusion is still under follow-up without disease recurrence. Moreover, significant decline in CA19-9 levels post infusion was observed in five (83.3%) patients, with reductions ranging from 51.3% to 96.1%.

All patients developed Grade 1 or 2 cytokine release syndrome (CRS) after the first satri-cel infusion. For the second infusion administered in one patient, grade 3 CRS accompanied by hypotension was observed, which was resolved within three days following tocilizumab treatment. All patients experienced gastrointestinal disorders, such as nausea and vomiting, which were all Grade 1 or 2. Only one case of Grade 3 gastritis occurred. No immune effector cell-associated neurotoxicity syndrome (ICANS) was reported.

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, “We are pleased to see that satri-cel has shown promising preliminary efficacy with a manageable safety profile in the highly challenging setting of pancreatic cancer adjuvant therapy. For patients at high risk of recurrence after surgical resection of pancreatic cancer, there are currently very few effective treatment options. In this trial, the sustained disease-free survival and marked declines in CA19-9 levels suggest that satri-cel, an innovative cellular immunotherapy, may clear minimal residual disease and potentially alter the disease course for these patients. Furthermore, we are actively advancing clinical trials exploring satri-cel for gastric cancer adjuvant therapy and as a sequential treatment following first-line gastric cancer therapy, with the goal of providing better curative opportunities for a broader patient population.”

About Satri-cel
Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on gastric/gastroesophageal junction adenocarcinoma (G/GEJA) and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib registrational trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), an investigator-initiated trial for satri-cel as a sequential therapy following first-line treatment in patients with advanced G/GEJA (CT041-CG4011, NCT07179484), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595).

The Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for satri-cel for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy on June 25, 2025. It has been granted Priority Review in May 2025 and Breakthrough Therapy Designation in March 2025 by the CDE. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA for the treatment of G/GEJA in September 2020.

About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

References

[1] Pancreatology. 2019 Mar;19(2):302-306.

[2] Sci Rep. 2020 Jan 28;10(1):1332.

 

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

By
Advertorial Desk
-

–          The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 in 65 participants with obesity or overweight.

–          The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life in participants with obesity in the Phase Ib study, supporting once-monthly administration.

–          Topline data from the 12-week Phase IIa study of ASC30 once-monthly SQ depot treatment formulation are expected in the first quarter of 2026.

–          The Company will host a conference call in Mandarin today at 10:00 a.m. China Standard Time. 

HONG KONG, Oct. 20, 2025 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces the recent completion of enrollment in the U.S. Phase IIa study for its once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 for the treatment of obesity (NCT06679959). All 65 participants are obese or overweight with at least one weight-related comorbidity.

The Phase IIa study of ASC30 once-monthly SQ depot treatment formulation is a 12-week, randomized, double-blind, placebo-controlled and multi-center study conducted in the U.S. to evaluate the safety, tolerability and efficacy in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity. The study consists of three cohorts of different doses, with a total of 65 participants. Topline data are expected in the first quarter of 2026.

The ultra-long-acting SQ depot treatment formulation of small molecule ASC30 demonstrated a 46-day observed half-life (as measured by time to 50% Cmax) in participants with obesity in the Phase Ib study (NCT06679959), supporting once-monthly administration. ASC30 treatment formulation’s terminal half-life was 36 days.

Furthermore, the U.S. Phase Ib single ascending dose (SAD) study demonstrated that compared to the trough concentration of ASC30 at Day 29, the ultra-long-acting SQ depot treatment formulation showed a peak-to-trough ratio of approximately 1.5 to 1. The proprietary SQ depot slow-release treatment formulation of ASC30 was developed from Ascletis’ Ultra-Long-Acting Platform (ULAP). Ascletis’ ULAP technology does not have the limitations of albumin-dependent half-life extension technology, currently being applied to many peptide drugs and candidates, which limits half-life extension to the half-life of albumin (approximately 20 days).

“Completing enrollment in this study is an important milestone, marking significant progress in our development of this innovative therapy,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Ascletis’ proprietary ultra-long-acting SQ depot treatment formulation of ASC30, with its 46-day observed half-life and favorable peak-to-trough ratio of approximately 1.5 to 1, demonstrated the potential to become a once-monthly treatment option for obesity. We are looking forward to topline data from this Phase IIa study in the first quarter of 2026.”

ASC30 was discovered and developed in-house at Ascletis as a first and only investigational small molecule GLP-1R biased agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management.

Conference Call

Ascletis will host a conference call in Mandarin today, October 20, 2025 at 10:00 a.m. China Standard Time. A live webcast of the call will be available via Tecent Meeting/ VooV Meeting, with the Meeting ID: 216-282-339, or access links of:

Chinese Mainland [1]: https://meeting.tencent.com/dm/8LbPT9Fs9HoW; or
International: https://voovmeeting.com/dm/8LbPT9Fs9HoW.

[1] Chinese Mainland: the People’s Republic of China, excluding, for the purpose of this press release, Hong Kong, Macau Special Administrative Region and Taiwan, China. 

About ASC30

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection administrations. ASC30 is a new chemical entity (NCE), with U.S. and global compound patent protection until 2044 without patent extensions. 

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies, Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact：

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com

Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com

ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

By
Advertorial Desk
-

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone,” HKEX: 2616),  an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas, today announced the first disclosure of preliminary Phase I data for CS2009 (a PD-1/VEGF/CTLA-4 trispecific antibody) and the Phase Ib study design for CS5001 (a ROR1-targeted Antibody-Drug Conjugate [ADC]) at the 2025 European Society for Medical Oncology (ESMO) Annual Congress.

Key Highlights of CS2009 Poster Presentation:

This also represents the first known clinical data publication of a PD-1/VEGF/CTLA-4 trispecific antibody to date.

CS2009-101 is a multi-regional phase Ⅰ study currently ongoing in Australia and China. The study evaluates the safety, tolerability, pharmacokinetics (PK)/ pharmacodynamics (PD), and antitumor activity of CS2009 in patients with advanced solid tumors.

Patients baseline characteristics:

  1. As of the data cutoff date, 72 patients with advanced solid tumors treated across 6 dose levels (DL1-6, 1-45 mg/kg); 72.2% remain on treatment.
  2. Heavily pretreated population: over 51% received prior immuno-oncology (IO) therapies. Median follow-up: only 1.9 months (range 0.1-6.7 months) at data cutoff.

Favorable safety and tolerability:

  1. Dose escalation completed with no dose-limiting toxicity (DLT) reported; maximum tolerated dose (MTD) not reached.
  2. No Grade 4 or 5 treatment-related adverse event (TRAE) observed. Incidence of Grade ≥3 TRAEs, immune-related AEs (irAEs), and VEGF-related TRAEs was 13.9%, 4.2%, and 2.8%, respectively.
  3. Only 1 treatment-emergent adverse event (TEAE) leading to drug permanent discontinuation observed (at DL4 [20 mg/kg]; 1.4% incidence).

Promising antitumor activity and high disease control rate (DCR):

CS2009 demonstrated encouraging anti-tumor activities across tumor types. As of the cutoff date, the overall follow-up duration remained limited, particularly in higher-dose cohorts where the majority patients had yet to reach the protocol-specified time point of post-baseline tumor assessment:

  1. 49/72 patients underwent at least one post-baseline tumor assessment by data cutoff.
  2. Despite limited follow-up duration, anti-tumor activity was observed across all dose levels with dose-dependent uptrend:
    • Among all 49 evaluable patients, overall response rate (ORR) was 12.2%; DCR was 71.4%. Efficacy data remains immature; with additional follow-up beyond the poster data cutoff, ORR was further improved to 14.3%.
    • Higher ORR (25.0%) at tentative recommended Phase 2 dose (RP2D, 30 mg/kg) and higher dose.
  3. Promising efficacy signals were observed across multiple tumor types within the short follow-up period:
    • Non-Small Cell Lung Cancer (NSCLC): ORR: 11.8%, DCR: 82.4%; Post-ESMO update: stable disease (SD)-to-partial response (PR) conversion observed, ORR further elevated to 17.6%; In AGA-negative subgroup, ORR reached 25%;
    • Ovarian Cancer (OC): ORR: 16.7%, DCR: 66.7%;
    • Triple-Negative Breast Cancer (TNBC): ORR: 25.0%, DCR: 75.0%;
    • Non–Clear Cell Renal Cell Carcinoma (nccRCC): ORR: 33.3%, DCR: 100.0%;
    • Soft Tissue Sarcoma (STS): ORR: 11.1%, DCR: 66.7%.

Favorable PK and PD profiles:

  1. Linear PK with half-life of 6-8 days supported every-three-week (Q3W) dosing, with no significant accumulation observed at cycle 3.
  2. PD profile demonstrated saturated receptor occupancy and robust T-cell activation/proliferation confirming PD-1/CTLA-4 blockade and deep and sustained VEGFA neutralization.
    • Receptor occupancy of PD-1/CTLA-4 on peripheral T cells reached saturation throughout dosing interval at doses ≥20 mg/kg.
    • On cycle 1 day 8, CS2009 induced notable, dose-dependent upregulation of Ki67 (proliferation due to PD-1 and CTLA-4 blockade) and ICOS (activation due to CTLA-4 blockade) expression on both CD4+ and CD8+ T cells, collectively demonstrating effective PD-1 and CTLA-4 inhibition.
    • Serum-free VEGFA reduced deeply and rapidly across all dose levels, and the effect sustained throughout dose intervals.

CStone has initiated PhaseⅡdose expansion study in first-line patients with selected tumor types for dose optimization and to generate data supporting registration trials in first-line NSCLC and other tumors as monotherapy or in combination therapies.

CS2009 Data Review Conference Call:

CStone will host an investor meeting to discuss presented data and future clinical development plan. The Company cordially invites all investors to attend this conference call.

Chinese-language session:

  • Date & Time: Monday, October 20, 2025, at 2:00 p.m. (Beijing Time)/2:00 a.m. (US Eastern Time)
  • Registration Link: Registration is required, please sign up via the link: https://s.comein.cn/iq2y9krs

English-language session:

Key Highlights of CS5001 ePoster Presentation:

  1. CS5001 phase Ib study aims to determine the RP2D and further evaluate the safety, tolerability, PK, and efficacy of CS5001 as a monotherapy and in combination with systemic therapies in selected tumor types.
  2. In monotherapy cohorts, Cohorts A-D enroll patients with chronic lymphocytic leukemia and other B-cell lymphomas, and Cohort I enrolls patients with ROR1-positive solid tumors. In combination therapy cohorts (E-H), CS5001 will be administered with standard systemic therapies (R-GemOx, R2 or R-CHOP) or with sugemalimab (an anti-PD-L1 monoclonal antibody). 
  3. Patient enrollment for CS5001 Phase Ib study commenced in December 2024 and is currently advancing smoothly at 30 sites across Australia, the United States, and China.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

Leading Competition Economist Dr. Luke Wainscoat Joins The Brattle Group

By
Advertorial Desk
-

SYDNEY, Oct. 20, 2025 /PRNewswire/ — The Brattle Group has welcomed Dr. Luke Wainscoat to its growing Sydney office as a Principal in the firm’s Antitrust & Competition practice. An economist with 20 years of experience, Dr. Wainscoat advises clients on complex competition, regulatory, and damages matters in Australia and New Zealand.

Brattle Principal Luke Wainscoat
Brattle Principal Luke Wainscoat

Recognized as one of Australia’s top competition economists by Lexology Index (previously Who’s Who Legal), Dr. Wainscoat’s expertise includes merger clearance processes, cartel investigations, anticompetitive agreements, and misuses of market power. He has served as an economic expert in the Federal Court of Australia and the Supreme Court of Victoria, and has worked on high-profile matters including the recent Apple v. Epic matter.

“Luke is an outstanding addition to Brattle’s expanding Sydney office and global antitrust team,” said Torben Voetmann, President and Principal at Brattle. “His extensive experience in competition and regulatory matters across Australia and New Zealand enhances our regional capabilities, and his leadership and insights strengthen the support we provide to clients throughout the Asia-Pacific region and globally.”

Dr. Wainscoat’s competition experience spans a wide range of industries, including digital platforms, online marketplaces, advertising, banking, consumer goods, pharmaceuticals, telecommunications, and more. He also advises clients and has provided expert testimony on commercial damages matters as well as those involving economic regulation in the electricity, gas, telecommunications, and rail sectors.

“I am thrilled to join Brattle at an exciting time for the firm and for competition policy in Australia,” said Dr. Wainscoat. “With the new merger regime in place, and the continuing growth in private antitrust matters, I look forward to providing clients with clear and focused advice for informing high-stakes decisions on competition matters.”

Dr. Wainscoat was previously an economist in consultancies in Sydney for the past 14 years. Earlier in his career, he worked at the United Kingdom’s Office of Fair Trading.

To learn more about Dr. Wainscoat, please see his full bio at https://www.brattle.com/experts/luke-wainscoat/.  

ABOUT BRATTLE
The Brattle Group answers complex economic, finance, and regulatory questions for corporations, law firms, and governments around the world. We are distinguished by the clarity of our insights and the credibility of our experts, which include leading international academics and industry specialists. Brattle has 500 talented professionals across four continents. For more information, please visit brattle.com.

The Brattle Group
The Brattle Group

Photo – https://laotiantimes.com/wp-content/uploads/2025/10/brattle_principal_luke_wainscoat.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/10/the_brattle_group_logo_v2.jpg

Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances

By
Advertorial Desk
-

SHANGHAI, Oct. 20, 2025 /PRNewswire/ — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment of Nicholas Jackson, Ph.D., as President of Global R&D and Alliances. Dr. Jackson will work closely with the Company’s CEO, Joshua Liang, to accelerate the development of Clover’s RSV+hMPV±PIV3 combination vaccine candidates and lead potential alliances with global collaborators.

“We are excited to welcome Nick back to Clover’s leadership team. His extensive experience in leading global cross-border vaccine development and partnerships will be invaluable as we continue to advance our potential best-in-class and first-in-class RSV+hMPV±PIV3 combination vaccine candidates leveraging our validated Trimer-Tag platform,” said Joshua Liang, Chief Executive Officer & Board Director of Clover.  

“I am honored to re-join Clover and look forward to helping advance and maximize global opportunities for Clover’s RSV+hMPV±PIV3 combination vaccine candidates, which have recently announced positive Phase I clinical data in older adults,” said Dr. Nicholas Jackson. “Additionally, Clover’s Trimer-Tag platform technology for vaccine development has a clinical safety database of 40,000+ doses and demonstrated commercial CMC scalability, which are critical for enabling late-stage development and globalization opportunities. I look forward to leading potential cross-border alliances in our efforts to maximize the impact on public health for Clover’s vaccine candidates and platform technology.”

Dr. Jackson has spent over 27 years in vaccine and infectious disease research and development roles, leading multiple successful global programs in viral and bacterial infectious disease targets. He has previously held leadership positions at esteemed infectious disease R&D organizations including GSK, Pfizer and Sanofi, where he was the Head of Global Research for Sanofi Pasteur, responsible for leading vaccine research and early development activities globally. Prior to re-joining Clover, in his most recent role with the Novo Nordisk Foundation Initiative for Vaccines and Immunity (NIVI), Dr. Jackson was the Executive Director and CEO.

Dr. Nicholas Jackson holds a Bachelor of Science degree from Oxford Brookes University, a Master of Science from the London School of Hygiene & Tropical Medicine, and a doctorate from the University of Warwick in the field of viral immunology.

About Clover 

Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.   

Clover Forward-looking Statements  

This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “going forward,” “intend,” “may,” “might,” “ought to,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements.   Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time.

 

Webull Reduces Minimum ASX Trading Fee To $1

By
Advertorial Desk
-
  • Webull Australia now offers the lowest-cost CHESS-sponsored brokerage fee minimums for trading ASX shares
  • The new pricing structure is paired with Webull’s industry-leading technology and free live pricing data
  • $1.00 minimum fees will be made available to Australian clients from 20 October 2025

SYDNEY, Oct. 20, 2025 /PRNewswire/ — Webull Securities (Australia) Pty Ltd (‘Webull Australia’), a subsidiary of Webull Corporation (NASDAQ: BULL), has today reduced ASX trading fees for CHESS-sponsored stocks to a minimum of $1.00, or 3-basis points. Australian and US ETF trades on the platform remain at $0 brokerage.

This move makes Webull Australia the lowest-cost CHESS-sponsored broker in Australia, and is being offered to all local users on a long-term basis.

The pricing structure for US share trading is also being simplified, moving to a minimum $1.00 for regular, extended, and overnight hours.

“This is a paradigm shift for CHESS-sponsored stockbroking in Australia. We are throwing down the gauntlet and setting a new benchmark in Australia to make share trading more inclusive for local traders and investors, regardless of trade size,” said Rob Talevski, CEO of Webull Securities Australia.“The benefit of being part of a profitable, NASDAQ-listed global broker is that, as was the case with our zero-dollar Australian and US ETF offering, these initiatives are announced as long-term measures to improve the investment landscape in Australia, and are not designed as short-term introductory offers. We’re introducing competition that will benefit local investors in a market that is often looked upon globally as an expensive place to trade.”

The new fee structure is available for all account types on the platform, including individual, SMSF, and trust accounts.

This new pricing scheme does not come at a cost to platform quality. Users will continue to have access to advanced features that typically attract monthly platform fees in Australia, including desktop trading, advanced charting, analyst ratings and real-time data, which are the result of Webull’s continuous development of the platform, since its launch in 2017.

Visit Webull.com.au to learn more.

###

About Webull Australia

Webull Securities (Australia) Pty. Ltd. is a leading financial services provider, holding an Australian Financial Services Licence (AFSL 536980) and regulated by the Australian Securities and Investments Commission (ASIC). As a trading participant of both the Australian Securities Exchange (ASX) and Cboe Australia, and a principal member of the Stockbrokers and Investment Advisers Association, Webull ensures the highest standards of service and security. Learn more at https://www.webull.com.au/.

About Webull

Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 24 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, fractional shares, and digital assets through Webull’s trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more a https://www.webullcorp.com/

Media contact:

Cognito for Webull
webull@cognitomedia.com

1...2,0842,0852,086...6,463Page 2,085 of 6,463